NCT06025630View on ClinicalTrials.gov

Targeting Endoplasmic Reticulum Stress in Human Hypertension

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Hypertension
Interventions
DRUG

TUDCA

Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)

DRUG

Placebo

Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.

Trial Locations (1)

76107

RECRUITING

University of North Texas Health Science Center, Fort Worth

All Listed Sponsors
lead

University of North Texas Health Science Center

OTHER